Entrada Therapeutics, Inc. (TRDA)

NGM – Real Time Price. Currency in USD

7.49

+0.45 (6.32%)

Market open: Aug 12, 2026, 3:22 PM EDT

7.04

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

25M

211M

129M

Cost of goods sold

-4M

-3M

-2M

Gross Profit

21M

207M

126M

-2M

Operating expenses (excl. COGS)

-177M

-160M

-129M

-95M

Operating Income

-156M

47M

-3M

-97M

Non-operating income, total

13M

19M

15M

Pretax income

-143M

66M

12M

-95M

Equity in earnings

Taxes

-924K

-859K

-19M

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-144M

66M

-7M

-95M

Discontinued operations

Net income

-144M

66M

-7M

-95M

Dilution adjustment

Preferred dividends

Entrada Therapeutics, Inc. (TRDA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Entrada Therapeutics, Inc. (TRDA)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Entrada Therapeutics, Inc. (TRDA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Entrada Therapeutics, Inc. (TRDA)

Income Statement (Annual)

Income Statement (Annual)